China FeNO Testing Market, By Type (Nitric Oxide Handheld Monitor, Nitric Oxide Standalone Monitor and Others), Indication (Eosinophilic Airway Inflammation, Atopic Asthma, Chronic Respiratory Symptoms, COPD with Mixed Inflammatory Phenotype, Eosinophilic Bronchitis, Pulmonary Arterial Hypertension, Corticosteroid Responsiveness, Cystic Fibrosis, Others), End User (Hospitals, Diagnostic Centers, Clinics, Ambulatory Surgical Centers, Homecare Setting, Others), Distribution Channel (Direct Tender, Retail Sales, Online Sales) – Industry Trends and Forecast to 2030.
China FeNO Testing Market Analysis and Size
Asthma is one of China's most common respiratory diseases, affecting millions of people. FeNo testing aids in the treatment and diagnosis of asthma diseases. Furthermore, asthma is one of the most common chronic airway diseases in both children and adults in China. The Chinese government is working to raise public awareness about asthma disease control and improve diagnostic procedures, which will provide opportunities in the FeNo testing market.
Data Bridge Market Research analyses that the FeNO testing market, which was USD 23,499.05 million in 2022, is expected to reach USD 66,564.09 million by 2030, at a CAGR of 13.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
China FeNO Testing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Nitric Oxide Handheld Monitor, Nitric Oxide Standalone Monitor and Others), Indication (Eosinophilic Airway Inflammation, Atopic Asthma, Chronic Respiratory Symptoms, COPD with Mixed Inflammatory Phenotype, Eosinophilic Bronchitis, Pulmonary Arterial Hypertension, Corticosteroid Responsiveness, Cystic Fibrosis, Others), End User (Hospitals, Diagnostic Centers, Clinics, Ambulatory Surgical Centers, Homecare Setting, Others), Distribution Channel (Direct Tender, Retail Sales, Online Sales)
|
|
Market Players Covered
|
Bedfont Scientific Ltd. (U.K.), Spirosure, Inc (U.S.), Medisoft Limited (Belgium), Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH) (Germany), Sunvou (China), RuiBreath (China), Circassia (U.K.), ECO MEDICS AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
A FeNO test or exhaled nitric oxide test can be used to determine how much lung inflammation is present and how well inhaled steroids are suppressing this inflammation in patients with allergic or eosinophilic asthma. FeNO testing is a quantitative, non-invasive, simple, and safe test that can be performed in primary care by a properly trained health care professional who is competent to deliver and interpret the results. The advantages of FeNO testing in primary care are patients are not required to be referred to a secondary care facility for additional testing and when combined with respiratory symptoms and lung function tests that are suggestive of asthma, a positive FeNO test supports a diagnosis.
China FeNO Testing Market Dynamics
Drivers
- New technological advancements in FeNo testing process
FeNo testing includes features in the technology of FeNo testing products such as nitric oxide handheld monitor and nitric oxide standalone monitor, which will impact the launch of new products by manufacturers into the market, thereby increasing market demand. Asthma is one of China's most common respiratory diseases, affecting millions of people. FeNo testing aids in the treatment and diagnosis of asthma diseases. Furthermore, asthma is one of the most common chronic airway diseases in both children and adults in China.
Opportunities
- Strategic business expansion activities
Strategic business expansion activities by major players to increase revenue share and product portfolio by launching innovative products are positively impacting the growth of the FeNO testing market. Caire Inc, a medical device manufacturer, acquired Spirosure Inc in 2020. The acquisition will allow Spirosure's technology to be applied to the company's market-leading oxygen solution portfolio. This acquisition is expected to help the company improve its operations and increase its revenue share.
Restraints/Challenges
- High cost of the device
High device costs and stringent government regulations governing product approval are expected to hamper the growth of the FeNO testing market. Furthermore, the lack of developed infrastructure in developing countries is expected to impede the adoption of advanced devices, limiting the target market's growth.
This FeNO testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the FeNO testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In August 2019, Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH) announced the launch of a new product for measuring fractional nitric oxide concentrations. This analyses the gas exhaled at home, which can aid in disease prevention.
- In 2020, Caire Inc, a medical device manufacturer, acquired Spirosure Inc. The acquisition will allow Spirosure's technology to be applied to the company's market-leading oxygen solution portfolio. This acquisition is expected to help the company improve its operations and increase its revenue share.
China FeNO Testing Market Scope
The FeNO testing market is segmented on the basis of type, indication, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Nitric Oxide Handheld Monitor
- Nitric Oxide Standalone Monitor
- Others
Indication
- Eosinophilic Airway Inflammation
- Atopic Asthma
- Chronic Respiratory Symptoms
- COPD with Mixed Inflammatory Phenotype
- Eosinophilic Bronchitis
- Pulmonary Arterial Hypertension
- Corticosteroid Responsiveness
- Cystic Fibrosis
- Others
End User
- Hospitals
- Diagnostic Centers
- Clinics
- Ambulatory Surgical Centers
- Homecare Setting
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Online Sales
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The FeNO testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for FeNO testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the FeNO testing market. The data is available for historic period 2011-2021.
Competitive Landscape and FeNO Testing Market Share Analysis
The FeNO testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to FeNO testing market.
Some of the major players operating in the FeNO testing market are:
- Bedfont Scientific Ltd. (U.K.)
- Spirosure, Inc (U.S.)
- Medisoft Limited (Belgium)
- Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH) (Germany)
- Sunvou (China)
- RuiBreath (China)
- Circassia (U.K.)
- ECO MEDICS AG (Switzerland)
SKU-